Immuneering (US:IMRX) Zhi Tong Cai Jing·2026-01-08 01:20Core Insights - Immuneering Corp. experienced a significant drop of approximately 21% in after-hours trading following the announcement of phase 2a clinical trial results for atebimetinib as a first-line therapy for pancreatic cancer [1] - The company reported a 12-month overall survival rate of 64% for patients treated with atebimetinib in combination with modified gemcitabine and albumin-bound paclitaxel, compared to a benchmark of 35% for current standard therapies [1] - The combination therapy also showed a 12-month overall response rate of 39%, while the standard therapy had a response rate of 23% [1] - The median progression-free survival for the combination therapy was 8.5 months, outperforming the standard therapy's 5.5 months [1] - Immuneering noted that only two grade 3 adverse events, neutropenia and anemia, were observed in more than 10% of patients [1] Comparative Analysis - Despite the positive data for atebimetinib, investors may compare it with other first-line therapies for pancreatic cancer currently in development, such as Verastem's avutometinib combined with defactinib and Revolution Medicines' daraxonarasib [2] - The reported overall response rate for the avutometinib combination therapy reached 83%, while daraxonarasib showed a response rate of 55% [2] - However, the median follow-up time for the results from Verastem and Revolution Medicines is relatively short [2]